Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus
Denali Therapeutics (DNLI) reported a narrower-than-expected loss in Q4 2025, with a loss of 73 cents per share against an estimated 75 cents. The company is focused on the potential commercial launch of tividenofusp alfa for Hunter syndrome, with the FDA extending its review timeline to April 5, 2026. Denali also provided updates on other pipeline candidates, including DNL126 for Sanfilippo syndrome type A, and collaborations with Takeda, Biogen, and Sanofi.